Prostate drug – San Francisco Chronicle

— San Francisco’s Medivation Inc. will receive a cash payment of $110 million from Astellas Pharma Inc. of Japan as part of a global agreement to develop and market MDV3100, Medivation’s experimental drug for the treatment of prostate cancer. More …

Read the whole story here: Prostate drug – San Francisco Chronicle

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply